Skip to main content

Table 1 Characteristics of the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients in the high-flow nasal therapy pulmonary rehabilitation (HFNT PR) and non-HFNT PR groups

From: Effect of high-flow nasal therapy during early pulmonary rehabilitation in patients with severe AECOPD: a randomized controlled study

CharacteristicNon-HFNT PR
(N = 22)
HFNT PR
(N = 22)
p value
Age, years73.1 ± 6.472.3 ± 7.70.703
Gender, M (%)15 (77.3)17 (77.3)0.728#
Smoking status  < 0.001#
 Non-smoker, n (%)1 (4)3 (13) 
 Current smoker, n (%)5 (22)0 (0) 
 Ex-smoker, n (%)16 (72)19 (86) 
Body-mass index, kg/m219.8 ± 3.120.3 ± 3.40.614
Pulmonary function test (PFT)
 FVC, % predicted normal80.0 ± 27.874.3 ± 16.20.412
 FEV1, % predicted normal36.5 ± 10.336.6 ± 8.00.911
 FEV1/FVC, %39.6 ± 12.840.2 ± 11.00.851
 Delta IC, L−0.22 ± 0.18−0.18 ± 0.170.513
6MWT
 6MWD, m128.5 ± 85.6177.0 ± 89.20.0524
 SpO2 pre/post 6MWT, %94.4/87.393.8/88.90.484/0.241
 HR pre/post 6MWT, %98.4/125.696.4/ 125.60.572/0.979
mMRC, score3.5 ± 0.53.1 ± 0.40.004
CAT score30.9 ± 2.128.9 ± 2.80.009
BODE score8.1 ± 1.37.1 ± 1.10.010
Laboratory
 WBCs, 103/μl14.8 ± 5.214.7 ± 4.40.951
 CRP, mg/dl8.4 ± 6.85.1 ± 5.60.086
 pH7.36 ± 0.087.36 ± 0.080.973
 PaCO2, mmHg51.5 ± 24.152.6 ± 20.30.8691
 PaO2, mmHg63.2 ± 15.366.1 ± 14.70.513
 HCO324.9 ± 4.226.3 ± 6.00.386
AE hospitalization in the previous PR 1 year, time2.6 ± 0.82.3 ± 0.70.167
Comorbidity
 CVD, n (%)15 (68)16 (72)0.741#
 GERD, n (%)6 (27)9 (40)0.340#
 Osteoporosis, n (%)7 (31)5 (22)0.498#
 Diabetes, n (%)6 (27)5 (22)0.728#
 Chronic renal failure, n (%)2 (9)3 (13)0.635#
 Anxiety, n (%)4 (18)3 (13)0.680#
Length of hospitalization, days8.6 ± 1.38.3 ± 1.90.459
  1. Note: Data are presented as the mean ± SD; # Analyzed by a Chi-squared test
  2. Abbreviations: GOLD Global Initiative for Chronic Obstructive Pulmonary Lung Disease; Group D: acute exacerbation (AE) ≥ 2; modified Medical Research Council (mMRC) ≥ 2, COPD assessment test (CAT) ≥ 10. FEV1, forced expiratory volume in the first second; FVC forced vital capacity; 6MWD, 6-min walking distance; mMRC modified Medical Research Council; BODE index body-mass index, degree of airflow obstruction and dyspnea, and exercise capacity; WBCs, white blood cells; CRP, C-reactive protein; PaCO2 partial pressure of carbon dioxide; PaO2 partial pressure of oxygen; GERD gastroesophageal reflux disease; CVD cardiovascular disease